TY -的T1 -不同的抗生素治疗方案的影响死亡率< em >鸟结核分枝杆菌< / em >复杂肺病(MAC-PD):以人群为基础的队列研究摩根富林明-欧洲呼吸杂志》乔和J - 10.1183/13993003.01875 -2019欧元SP - 1901875 AU -莎拉·k·Brode AU -汉娜涌AU -迈克尔·A·Campitelli盟杰弗里·c·邝Alex Marchand-Austin AU -苏特拉德哈尔Rinku盟盟——凯文·l·温斯洛普盟弗朗西斯b Jamieson AU -西奥多·k·马拉Y1 - 2020/01/01 UR - //www.qdcxjkg.com/content/early/2020/04/08/13993003.01875 - 2019. -抽象N2 -循证指南建议的组合macrolide-ethambutol-rifamycin作为一线治疗复杂鸟结核分枝杆菌肺病(MAC-PD) [1]。这个方案是否导致改善生存是未知的。FootnotesThis手稿最近发表在《欧洲呼吸杂志》上。这里发表周全之前接受的形式排版,我们的生产团队。这些生产过程完成后,作者已经批准结果证明,本文将最新一期的ERJ在线。请打开或下载PDF查看这篇文章。利益冲突:Brode博士报告赠款Insmed制药、勃林格殷格翰集团的个人费用,个人费用从Astra-Zeneca赠款从加拿大卫生研究院的研究(CIHR),在提交工作。利益冲突:钟女士没有披露。利益冲突:Campitelli先生没有披露。利益冲突:邝博士没有披露。利益冲突:Sutradhar博士没有披露。利益冲突:Marchand-Austin先生没有披露。Conflict of interest: Dr. Winthrop reports grants and personal fees from Insmed, personal fees from Johnson &amp; Johnson, personal fees from Paratek , personal fees from Red Hill Biopharma, personal fees from Horizon, outside the submitted work.Conflict of interest: Dr. Jamieson has nothing to disclose.Conflict of interest: Dr. Marras reports grants and personal fees from Insmed, personal fees from Astra-Zeneca, personal fees from Horizon, personal fees from RedHill, personal fees from France Foundation, personal fees from Novartis, outside the submitted work. ER -